A business professional who has served as an executive officer in both privately held and publicly traded companies, an investment banker and a corporate attorney. Demonstrated experience in all aspects of financial and business management, strategy and operations including operations management, strategic planning, technology outlicensing, legal, mergers and acquisitions, IPO’s, private placements, finance and accounting, facilities, human resources, IT systems and corporate communications.
Specialties: As CFO raised over $2 billion in equity and debt financings for emerging public and private companies
Designed and executed financial and corporate development strategies
Built and managed operational departments including finance and accounting, human resources, facilities, corporate communications and information systems
Worked as both an investment banker and corporate attorney
Behtash Bahador is the Senior Director of Community Engagement & Partnerships at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.
I am interested in acting as an entrepreneur to create companies that can build cultures and products that change the world. I am a versatile player willing to take on many different positions because of my background in both technology (chemistry, biology, software) and business. I prefer the role of visionary and to work to build a team, culture, product, and partnerships. I like the challenge of creating innovative solutions to hard underserved problems.
I am currently focused on my start-up ventures including Graticule (Digital accelerators for Advanced real world data), Courage Therapeutics (medical discovery for eating disorders), and advocacy work towards improving research, treatment, and payment for Anorexia Nervosa.
Molly James is the Associate Director of Strategic Sourcing at Beam Therapeutics. In this role she manages all vendors and leads strategic partnerships for the development organization within Beam. She has over 10 years of experience in strategic sourcing and vendor management within the pharmaceutical industry.
Hyun has been a part of AOBiome’s clinical pipeline leadership since 2016. Hyun brings over 25 years of drug development experience in the pharma and biotech industry. Prior to this, Hyun has led Clinical and R&D programs and departments at Pfizer, Anika Therapeutics, Transport Pharmaceuticals, and Olympus Biotech. He started his career at Genetics Institute and Wyeth, advancing R&D programs into the clinic. He attended Brown University where he studied Biomedical Engineering and completed a PhD in Medical Science.
AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company’s portfolio includes multiple clinical-stage programs in atopic dermatitis, rosacea, and acne, as well as additional programs targeting diverse inflammatory indications.
Mr. Adams has been a founder or co-founder of life science and technology based companies in Massachusetts for the past several years. Mr. Adams has been instrumental in developing new proprietary therapeutic and medical device technologies and bringing the technologies to commercialization. The companies he has founded include, Compellis Pharmaceuticals, a developer of therapeutics to treat obesity and its co-morbidities, diabetes and hypertension and Mosaic Technologies, a venture backed MIT spin-out genomics company that developed patented technologies for genetic analysis and detection.
Chris is the holder of more than 20 issued US and international patents for medical devices and pharmaceuticals.
Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to joining Anavex®, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. His career experience also includes working as an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, as well as serving as the head of healthcare investment banking at Brimberg & Co. in New York. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.
Hollie Schmidt is the VP of Scientific Operations at Accelerated Cure Project for Multiple Sclerosis. She co-chairs the Research Committee of iConquerMS™, a research cohort established to perform and support patient-centered research in MS. She also founded and leads the MS Minority Research Engagement Partnership Network, a multi-stakeholder initiative aimed at increasing racial and ethnic diversity in MS research studies.
